Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's Executive Vice President and Chief Scientific & Technical Officer, Cokey Nguyen, Ph.D., will present on Monday, September 9, 2024, at 6:30 a.m. PDT / 9:30 a.m. EDT.

Atara specializes in developing transformative therapies for patients with cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform. Investors and interested parties can access a live webcast of the presentation through the Investors and Media section of atarabio.com. An archived replay will be available on the company's website for 30 days following the live presentation.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 6:30 a.m. PDT / 9:30 a.m. EDT.

A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903784669/en/

Investor and Media Relations:

Jason Awe, Ph.D.

Head of Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

When is Atara Biotherapeutics (ATRA) presenting at the H.C. Wainwright Global Investment Conference?

Atara Biotherapeutics (ATRA) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 6:30 a.m. PDT / 9:30 a.m. EDT.

Who will be presenting for Atara Biotherapeutics (ATRA) at the investment conference?

Cokey Nguyen, Ph.D., Executive Vice President and Chief Scientific & Technical Officer of Atara Biotherapeutics, will be presenting at the conference.

How can investors access Atara Biotherapeutics' (ATRA) presentation at the H.C. Wainwright conference?

Investors can access a live webcast of the presentation through the Investors and Media section of atarabio.com. An archived replay will be available on the company's website for 30 days after the live presentation.

What is the focus of Atara Biotherapeutics' (ATRA) research and development?

Atara Biotherapeutics (ATRA) focuses on T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with cancer and autoimmune diseases.